3M Unveils Intelligent Inhaler Designed to Help Control Spiraling Costs of Respiratory Disease

Technology aims to solve patient competence and adherence
challenges, minimizing burden on health care providers and payers

ST. PAUL, Minn.–(BUSINESS WIRE)–Research shows that an estimated 334 million people have asthma
worldwide, and 65 million people have moderate to severe COPD – a number
that is expected to rise 24 percent by the year 2034 to make COPD the
world’s third leading cause of death.(1,2,3) As cases
increase, driven by the aging population, hospitals and care providers
continue to see low levels of adherence and poor and inconsistent
competence using current treatment devices. This has led to sub-optimal
outcomes and higher rates of hospital admissions. Answering the need for
a solution to device misuse and adherence issues, 3M Drug Delivery
Systems introduces the 3M™ Intelligent Control Inhaler, an intuitive,
fully-integrated device that delivers accurate doses to patients, whilst
providing on-screen instructions for use and feedback to the patient and
health care provider via an app.

“Providing an effective and intuitive delivery method for respiratory
disease treatment is critical to patients, health care providers and
payers alike,” said Louise Righton, Global Marketing Operations Manager,
3M Drug Delivery Systems. “Poor technique in using an inhaler, coupled
with the challenges of getting patients to adhere to their medication
protocols, can lead to exacerbations, increased use of health care
resources and ultimately, a burden on health care systems. By increasing
competence and adherence, we can realize better patient outcomes and
reduce health care costs.”

The 3M Intelligent Control Inhaler provides a number of unique features
that offer opportunities to improve outcomes by reducing patient
variability and errors, and providing data on use to health care
providers and payers:

  • Controlled inspiration: a combination of breath actuation with
    innovative technology to control inspiratory flow rate significantly
    reduces errors in technique, and results in a much higher level of
    consistency of drug delivery between breaths and between patients.
  • Integrated patient instructions: the inhaler’s patient-proof
    design gives patients confidence to use the inhaler correctly and
    helps eliminate critical errors in use, as well as minimizing the
    resources dedicated to training patients in correct inhalation
  • Fully integrated device: the dose is registered when the
    patient correctly inhales medication rather than on actuation of the
    device, delivering greater accuracy of information for the patient,
    and cost-savings for health care providers who can avoid unnecessary
    switches and treatment escalation.
  • Capture of inspiration data: the inhaler utilizes a data
    management platform to record not only device usage, but also
    inspiration profiles to help monitor disease progression, further
    supporting informed treatment decisions.

The device will be developed in partnership with a pharmaceutical
company, and is expected to be in wide use by the end of the decade.

“We’ve done a tremendous amount of research during the development of
this technology with patients, health care providers, and payers,” said
Dr Steven Wick, Technical Director, 3M Drug Delivery Systems. “With 60
years of experience in inhalation technologies, and 30 years in health
information systems, 3M is uniquely qualified to bring forth a solution
that is a definitive win for each of these stakeholders. Nothing has
worked to improve inhaler technique over the past 25 years – and here we
have a connected device to improve both competence AND adherence. The
need for a smarter solution has never been greater, and 3M intends to
put greater control of respiratory disease into the hands of patients,
health care providers and payers.”

For more information on the 3M Intelligent Control Inhaler, call
1-800-643-8086 (US), 44-1509-613034 (UK) or click

About 3M Drug Delivery Systems

3M Drug Delivery Systems partners with pharmaceutical and biotech
companies to develop and manufacture pharmaceutical products using 3M’s
inhalation, transdermal or microneedle drug delivery technology. 3M
offers a full range of feasibility, development and manufacturing
capabilities to help bring products to market. Regulatory expertise,
quality assurance, operations, marketed product support and other
in-house resources are available for each step of the development and
commercialization process. For more information, please visit www.3M.com/dds
or call 1-800-643-8086.

About 3M

At 3M, we apply science in collaborative ways to improve lives daily.
With $30 billion in sales, our 90,000 employees connect with customers
all around the world. Learn more about 3M’s creative solutions to the
world’s problems at www.3M.com or
on Twitter @3M or @3MNewsroom.

3M is a trademark of 3M Company.

1 World Health Organisation. Available at: http://www.who.int/respiratory/copd/burden/en/
[last accessed November 26, 2015]

2 COPD: Chronic Obstructive Pulmonary Disease

3 Datamonitor Healthcare. Chronic obstructive pulmonary
disease: Epidemiology. 2015


For 3M
Michael Gugala, 612-342-9604
Karwoski & Courage